Recent reports have highlighted a significant surge in spending on GLP-1 drugs, particularly Ozempic and Wegovy, which have become the top-selling drugs with expenditures doubling to $38.6 billion last year. These drugs, which mimic a naturally occurring hormone that signals satiety, are reshaping the U.S. health and fitness industries. However, the cost implications are staggering, with estimates by MIT's Jonathan Gruber suggesting that expanding insurance coverage for these drugs by the US government could reach $1 trillion annually, potentially surpassing the cost of the U.S. military. This has raised questions about the sustainability and economic impact of such widespread use.
Injected drugs like Wegovy and its predecessor, the diabetes medication Ozempic, are reshaping the U.S. health and fitness industries. https://t.co/NF71vpSRnJ
Johann Hari, who has struggled with his weight since childhood, decided to try Ozempic and was delighted with the result. Then he talked to scientists about its possible impact on the brain and began to have second thoughts ⬇️ https://t.co/oKNTjTUUrO
#Ozempic, a drug to treat Type 2 #diabetes, has been going viral for its #WeightLoss side-effects. But what happens if you stop taking it? | @mehaksabharwal writes https://t.co/MgBhwZvtsD
A Big Week for GLP-1 Drugs https://t.co/jnsxNRoyuU https://t.co/DUx4cZXHZv
What happens if you stop taking Ozempic for weight loss? https://t.co/oKcCFfIsK6
Ozempic, a drug to treat Type 2 #diabetes, has been going viral for its #WeightLoss side effects. But what happens if you stop taking it? | @mehaksabharwal writes https://t.co/MgBhwZvtsD
Very interesting question on whether the new GLP-1 drugs will save more money than they cost the healthcare system (and insurance) since it's not yet known how long you need to take these drugs to sustain the benefits (forever?) for #obesity and #diabetes. New studies suggest…
What happens when a best-selling author decides to try Ozempic? He goes down a rabbit hole of research, emerging slimmer but not altogether unconcerned – and with a book about the experience. https://t.co/cttgxsklX8
GLP-1 treatments were a main driver of the increase in overall drug spending by health entities like pharmacies and hospitals last year, study shows. https://t.co/XY0dbJtuo5
Are GLP-1s the silver bullet for weight loss that many people believe them to be? One obesity medicine physician explains why the market might be smaller than expected: https://t.co/q831GmLSHu #GSExchanges https://t.co/Pspr3BIoeE
@BrianCDeese recently calculated that providing GLP-1 drugs for all Americans with obesity could soon cost $1 trillion annually. That would make semaglutide more expensive than the US military. https://t.co/ftGTp6Id4e
Spending on GLP-1 drugs has quickly surpassed spending on insulin products in the last few years. https://t.co/ioENrd3ZNx
GLP-1Ra Spending would likely have been even higher if not limited by manufacturing limitations https://t.co/j3pU2UAaZX by @elaineywchen @statnews https://t.co/5DYJrtz0tF https://t.co/laxEmdRl3l
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about GLP-1 spending, Biosimilar patient costs, and more news.. https://t.co/BBAkkq9q2p #pharma #weight #obesity #Alzheimer #Harvard #biosimilars #insulin #Wegovy #Ozempic $NVO $LLY $BIIB $NVS $SNY $ESAIY $CVS $CI $UNH
Two reports out this morning show spending on GLP-1 drugs have surged, and is set to climb still more this year and beyond. Health entities spent $38.6 billion on Ozempic/Wegovy last year (double the year before), making it the top-seller among all drugs https://t.co/P3Vi6ozBcj
Ozempic, an injectable medication, operates by emulating a hormone naturally produced in the body that signals satiety to the brain, effectively reducing appetite and facilitating weight loss. https://t.co/TejcmLcOeM
At current prices, it would cost the US government a staggering sum to expand insurance coverage for GLP-1s, according to MIT’s Jonathan Gruber: https://t.co/1KMiFQlxRo #GSExchanges https://t.co/kwtZ6uFmZY